$145.79
0[0.00%]
At close: Apr 22
$145.79
0[0.00%]
PreMarket: 4:00PM EDT
Alnylam Pharmaceuticals
(NASDAQ:ALNY)Alnylam Pharmaceuticals Stock (NASDAQ:ALNY), Guidance and Forecast
Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period.
Date Announced | ticker | Company Name | Period | Period Year | Min EPS | Max EPS | Estimate | Min Rev | Max Rev | Revenue Estimate | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/15/2024 | ALNY | Alnylam Pharmaceuticals | FY | 2024 | — | — | — | $1.73B | $1.93B | $1.78B | Get Alert |
| 11/02/2023 | ALNY | Alnylam Pharmaceuticals | FY | 2023 | — | — | — | $1.77B | $1.91B | $1.44B | Get Alert |
| 08/03/2023 | ALNY | Alnylam Pharmaceuticals | FY | 2023 | — | — | — | $1.30B | $1.46B | $1.44B | Get Alert |
| 05/04/2023 | ALNY | Alnylam Pharmaceuticals | FY | 2023 | — | — | — | $1.30B | $1.46B | $1.39B | Get Alert |
| 02/23/2023 | ALNY | Alnylam Pharmaceuticals | FY | 2023 | — | — | — | $1.30B | $1.46B | $1.48B | Get Alert |
| 10/27/2022 | ALNY | Alnylam Pharmaceuticals | FY | 2022 | — | — | — | $970.00M | $1.08B | $1.07B | Get Alert |
| 07/28/2022 | ALNY | Alnylam Pharmaceuticals | FY | 2022 | — | — | — | $970.00M | $1.08B | $1.09B | Get Alert |
| 04/28/2022 | ALNY | Alnylam Pharmaceuticals | FY | 2022 | — | — | — | $870.00M | $930.00M | $1.17B | Get Alert |
| 10/28/2021 | ALNY | Alnylam Pharmaceuticals | FY | 2021 | — | — | — | $790.00M | $865.00M | $853.11M | Get Alert |
| 08/03/2021 | ALNY | Alnylam Pharmaceuticals | FY | 2021 | — | — | — | $790.00M | $865.00M | $837.45M | Get Alert |
| 04/29/2021 | ALNY | Alnylam Pharmaceuticals | FY | 2021 | — | — | — | $760.00M | $860.00M | $824.74M | Get Alert |
| 02/11/2021 | ALNY | Alnylam Pharmaceuticals | FY | 2021 | — | — | — | $760.00M | $860.00M | $796.86M | Get Alert |
FAQ
What is the most recent guidance for Alnylam Pharmaceuticals (ALNY)?
There have been no specific sales or earnings guidance reported for Alnylam Pharmaceuticals in recent months.
Browse guidance and forecast on all stocks.